Noveris Health Sciences Inc.
MYCOF
$2.00
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.10% | -99.23% | -114.22% | -68.10% | -42.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.10% | 100.25% | -106.71% | -89.34% | -44.14% |
| Operating Income | 12.10% | -100.25% | 106.71% | 89.34% | 44.14% |
| Income Before Tax | -458.31% | 26.85% | 103.67% | 99.52% | 72.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -458.31% | 26.85% | 103.67% | 99.52% | 72.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -458.31% | 26.85% | 103.67% | 99.52% | 72.37% |
| EBIT | 12.10% | -100.25% | 106.71% | 89.34% | 44.14% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 56.58% | 26.59% | 103.67% | 99.52% | 75.92% |
| Normalized Basic EPS | 73.75% | -126.78% | 103.67% | 95.11% | 60.54% |
| EPS Diluted | 56.58% | 26.59% | 103.67% | 99.52% | 75.92% |
| Normalized Diluted EPS | 73.75% | -126.78% | 103.67% | 95.11% | 60.54% |
| Average Basic Shares Outstanding | 1,185.08% | 0.20% | 0.00% | 0.92% | 14.78% |
| Average Diluted Shares Outstanding | 1,185.08% | 0.20% | 0.00% | 0.92% | 14.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |